Besides, further experiments on other immune and HRS cells are necessary for investigating the differentiation/maturation, inflammatory response and cell death, as well as the molecular mechanisms underlying the regulation of A20/CYLD on function of Dox-treated cells in cHL patients. The gene discussed is TNFAIP3; the disease is classic Hodgkin lymphoma.